Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Premier, Inc. Reports Fiscal-Year 2023 Third-Quarter Results
Premier, Inc. Reports Fiscal-Year 2023 Third-Quarter Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 third quarter ended March 31, 2023 and provided

Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23
Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23


Agilent Technologies Inc. (NYSE: A) will release financial results and hold an earnings conference call for the second quarter of fiscal year 2023 after the stock market closes on Tuesday, May 23

STAAR Surgical to Report First Quarter Results on May 3, 2023
STAAR Surgical to Report First Quarter Results on May 3, 2023


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter

Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. FDA has renewed its

Dexcom Reports First Quarter 2023 Financial Results
Dexcom Reports First Quarter 2023 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023.



First Quarter 2023 Financial Highlights:




  • Revenue grew 18% versus the same

Dexcom Reports First Quarter 2023 Financial Results
Dexcom Reports First Quarter 2023 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023.



First Quarter 2023 Financial Highlights:




  • Revenue grew 18% versus the same

Acadia Healthcare Reports First Quarter 2023 Results
Acadia Healthcare Reports First Quarter 2023 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2023.



First Quarter Highlights




  • Revenue totaled $704.3 million, an

Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes


DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes

Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes


DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board